Global Breast Cancer Diagnostics Market Size, Trends, and Growth Opportunity, By Test Type (Imaging, Biopsy, Genomic Test, Blood Test, and Others), By Type (Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer), By End User (Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others) Distribution Channel (Direct Tender, Retail Sales, and Others), By Region and Forecast to 2030.
Global Breast Cancer Diagnostics Market
The Global Breast Cancer Diagnostics Market was valued at USD 5.2 billion in 2022 and is expected to reach USD 7.5 billion by 2030, at a CAGR 3.04% during the forecast period 2023- 2030.
The most prevalent disease in the population is breast cancer, which mostly affects females with proliferative disorders. Breast tissues are where breast cancer mostly manifests itself. Breast lumps, altered breast size, and shape, discharge from the nipples, and itchy, scaly red spots on the skin are all indications of breast cancer. Imaging, biopsy, genomic studies, blood tests, and other procedures are the main types of diagnostics for breast cancer. A biopsy is a procedure used to remove a sample of cells or tissue from the body so that it may be examined in a lab. The technologies in question include immunohistochemistry (IHC), comparative genomic hybridization (CGH), fluorescent in situ hybridization (FISH), and other technologies.
Market Drivers
The rising incidence of breast cancer worldwide. According to figures from the World Health Organization (WHO) for 2021, 2.3 million women worldwide received a breast cancer diagnosis in 2020. Furthermore, according to the same source, 7.8 million women will still be living by the end of 2020 who have received a breast cancer diagnosis in the previous five years, making it the most common cancer in the world. Hence, the demand for breast cancer diagnostics has increased as breast cancer prevalence has increased globally which is anticipated to boost the market growth. The numerous initiatives launched by the various national governments to raise awareness about early screening and diagnosis are also major factors driving the growth of the breast cancer diagnostics market.
Market Restraints
One major problem impeding the expansion of the market for breast cancer diagnostics is the high cost of a breast cancer diagnosis. With the start of the diagnostic stage of the disease, the price of a breast cancer diagnosis often increased. HealthMatch estimates that the entire cost of treating breast cancer in 2020 will be between $20,000 and $100,000. The cost of the diagnostic alone varied from $151 to $751 depending on the location. As a result, a breast cancer diagnosis is an expensive process that is out of reach for most people, which restricts the market for breast cancer diagnostics from expanding.
Market Segmentation
The Global Breast Cancer Diagnostics Market is segmented into Test Type, Type, End User, and Distribution Channel. Based on Test Type, the market is classified into Imaging, Biopsy, Genomic Test, Blood Test, and Others. Based on Type, the market is divided into Ductal In Situ Carcinoma, Invasive Ductal Carcinoma, Inflammatory Breast Cancer, and Metastatic Breast Cancer. Based on End Users, the market is segmented into Hospitals, Clinics, Research and Academic Institutes, Diagnostic Centers, and Others. Based on Distribution Channel, the market is bifurcated into Direct Tender, Retail Sales, and Others.
Regional Analysis
The Global Breast Cancer Diagnostics Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. North America is anticipated to dominate the market growth during the forecast period. The presence of large players, established diagnostic and screening infrastructure, technological breakthroughs, high patient awareness, and attractive reimbursement regulations are the main drivers of this region's dominance. The market expansion is anticipated to be boosted by the rising investment in breast cancer R&D. Due to the significant presence of prominent players like F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., ABBOTT, and others, the U.S. leads the North American area. Asia Pacific is anticipated to experience the greatest CAGR over the forecast period. Due to the rising incidence of breast cancer and the adoption of cutting-edge diagnostic methods, the market for breast cancer diagnostics is driving the market growth.
Key Development
In November 2022, to make the diagnostic quality associated with high-end cart-based ultrasound systems available to more patients, Koninklijke Philips N.V. announced the global launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting. It has good performance and image quality, and it is portable. In November 2022, a multi-year value relationship has been established by Siemens Healthineers and Atrium Health, a premier not-for-profit healthcare organization recognized for its innovative pediatric, cancer, and cardiac care programs. This collaborative partnership aims to increase economic mobility, health equity, and access to care in the Southeast United States, where Atrium Health provides its services.
Key Players
Various key players are discussed in the Global Breast Cancer Diagnostics Market Report including: F-Hoffmann La Roche Ltd., Siemens Healthcare GmbH, General Electric, Koninklijke Philips N.V., FUJIFILM Corporation, Abbott, Hologic, Inc., OncoStem, Provista Diagnostics, Thermo Fisher Scientific Inc., and Myriad Genetics, Inc.
Market Taxonomy
By Test Type
• Imaging
• Biopsy
• Genomic Test
• Blood Test
• Others
By Type
• Ductal In Situ Carcinoma
• Invasive Ductal Carcinoma
• Inflammatory Breast Cancer
• Metastatic Breast Cancer
By End User
• Hospitals
• Clinics
• Research and Academic Institutes
• Diagnostic Centers
• Others
By Distribution Channel
• Direct Tender
• Retail Sales
• Others
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa
Global Breast Cancer Diagnostics Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Breast Cancer Diagnostics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing economic downturn
4.2.6 Post covid-19 world Supply & Demand conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Breast Cancer Diagnostics Market, By Test Type
5.1 Y-o-Y Growth Comparison, By Test Type
5.2 Global Breast Cancer Diagnostics Market Share Analysis, By Test Type
5.3 Global Breast Cancer Diagnostics Market Size and Forecast, By Test Type
5.3.1 Imaging, Biopsy
5.3.2 Genomic Test
5.3.3 Blood Test
5.3.4 Others
6 Global Breast Cancer Diagnostics Market, By Type
6.1 Y-o-Y Growth Comparison, By Type
6.2 Global Breast Cancer Diagnostics Market Share Analysis, By Type
6.3 Global Breast Cancer Diagnostics Market Size and Forecast, By Type
6.3.1 Ductal In Situ Carcinoma
6.3.2 Invasive Ductal Carcinoma
6.3.3 Inflammatory Breast Cancer
6.3.4 Metastatic Breast Cancer
8 Global Breast Cancer Diagnostics Market, By End User
8.1 Y-o-Y Growth Comparison, By End User
8.2 Global Breast Cancer Diagnostics Market Share Analysis, By End User
8.3 Global Breast Cancer Diagnostics Market Size and Forecast, By End User
8.3.1 Hospitals
8.3.2 Clinics
8.3.3 Research and Academic Institutes
8.3.4 Diagnostic Centers
8.3.5 Others
9 Global Breast Cancer Diagnostics Market, By Distribution Channel
9.1 Y-o-Y Growth Comparison, By Distribution Channel
9.2 Global Breast Cancer Diagnostics Market Share Analysis, By Distribution Channel
9.3 Global Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
9.3.1 Hospitals
9.3.2 Clinics
9.3.3 Others
10 Global Breast Cancer Diagnostics Market, By Region
10.1 Global Breast Cancer Diagnostics Market Share Analysis, By Region
10.2. Global Breast Cancer Diagnostics Market Size and Forecast, By Region
11 North America Breast Cancer Diagnostics Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 North America Breast Cancer Diagnostics Market Share Analysis, By Test Type
11.3 North America Breast Cancer Diagnostics Market Size and Forecast, By Type
11.4 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By End User
11.5 North America Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
11.6 North America Breast Cancer Diagnostics Market Size and Forecast, By Country
11.6.1 U.S.
11.6.2 Canada
11.6.3 Mexico
12 Europe Breast Cancer Diagnostics Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Europe Breast Cancer Diagnostics Market Share Analysis, By Test Type
12.3 Europe Breast Cancer Diagnostics Market Size and Forecast, By Type
12.4 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By End User
12.5 Europe Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
12.6 Europe Breast Cancer Diagnostics Market Size and Forecast, By Country
12.6.1 Germany
12.7.2 France
12.7.3 UK
12.7.4 Rest of Europe
13 Asia Pacific Breast Cancer Diagnostics Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Asia Pacific Breast Cancer Diagnostics Market Share Analysis, By Test Type
13.3 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By Type
13.4 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By End User
13.5 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
13.6 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By Country
13.6.1 China
13.6.2 Japan
13.6.3 India
13.6.4 Rest of Asia Pacific
14 6atin America Breast Cancer Diagnostics Market Analysis and Forecast (2023-2030)
14.1 Introduction
14.2 Latin America Breast Cancer Diagnostics Market Share Analysis, By Test Type
14.3 Latin America Breast Cancer Diagnostics Market Size and Forecast, By Type
14.4 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By End User
14.5 Latin America Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
14.6 Latin America Breast Cancer Diagnostics Market Size and Forecast, Country
14.6.1 Brazil
14.6.2 Rest of Latin America
15 Middle East Breast Cancer Diagnostics Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 Middle East Breast Cancer Diagnostics Market Share Analysis, By Test Type
15.3 Middle East Breast Cancer Diagnostics Market Size and Forecast, By Type
15.4 Asia Pacific Breast Cancer Diagnostics Market Size and Forecast, By End User
15.5 Middle East Breast Cancer Diagnostics Market Size and Forecast, By Distribution Channel
15.6 Middle East Breast Cancer Diagnostics Market Size and Forecast, By Country
15.6.1 Saudi Arabia
15.6.2 UAE
15.6.3 Egypt
15.6.4 Kuwait
15.6.5 South Africa
16 Competitive Analysis
16.1 Competition Dashboard
16.2 Market share Analysis of Top Vendors
16.3 Key Development Strategies
17 Company Profiles
17.1 F-Hoffmann La Roche Ltd.
17.1.1 Overview
17.1.2 Offerings
17.1.3 Key Financials
17.1.4 Business Segment & Geographic Overview
17.1.5 Key Market Developments
17.1.6 Key Strategies
17.2 Siemens Healthcare GmbH
17.2.1 Overview
17.2.2 Offerings
17.2.3 Key Financials
17.2.4 Business Segment & Geographic Overview
17.2.5 Key Market Developments
17.2.6 Key Strategies
17.3 General Electric
17.3.1 Overview
17.3.2 Offerings
17.3.3 Key Financials
17.3.4 Business Segment & Geographic Overview
17.3.5 Key Market Developments
17.3.6 Key Strategies
17.4 Koninklijke Philips N.V.
17.4.1 Overview
17.4.2 Offerings
17.4.3 Key Financials
17.4.4 Business Segment & Geographic Overview
17.4.5 Key Market Developments
17.4.6 Key Strategies
17.5 FUJIFILM Corporation
17.5.1 Overview
17.5.2 Offerings
17.5.3 Key Financials
17.5.4 Business Segment & Geographic Overview
17.5.5 Key Market Developments
17.5.6 Key Strategies
17.6 Abbott
17.6.1 Overview
17.6.2 Offerings
17.6.3 Key Financials
17.6.4 Business Segment & Geographic Overview
17.6.5 Key Market Developments
17.6.6 Key Strategies
17.7 Hologic, Inc.
17.7.1 Overview
17.7.2 Offerings
17.7.3 Key Financials
17.7.4 Business Segment & Geographic Overview
17.7.5 Key Market Developments
17.7.6 Key Strategies
17.8 OncoStem
17.8.1 Overview
17.8.2 Offerings
17.8.3 Key Financials
17.8.4 Business Segment & Geographic Overview
17.8.5 Key Market Developments
17.8.6 Key Strategies
17.9 Provista Diagnostics
17.9.1 Overview
17.9.2 Offerings
17.9.3 Key Financials
17.9.4 Business Segment & Geographic Overview
17.9.5 Key Market Developments
17.9.6 Key Strategies
17.10 Thermo Fisher Scientific Inc.
17.10.1 Overview
17.10.2 Offerings
17.10.3 Key Financials
17.10.4 Business Segment & Geographic Overview
17.10.5 Key Market Developments
17.10.6 Key Strategies
17.11 Myriad Genetics, Inc.
17.11.1 Overview
17.11.2 Offerings
17.11.3 Key Financials
17.11.4 Business Segment & Geographic Overview
17.11.5 Key Market Developments
17.11.6 Key Strategies
